5009113), a grant from the Program of Shenzhen Science and techno

5009113), a grant from the Program of Shenzhen Science and technology (no. 200903002). References 1. Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ: Typhoid fever. N Engl J Med 2002, 347:1770–82.PubMedSelleck Trichostatin A CrossRef 2.

Parry CM: The treatment of multidrug resistant and nalidixic acid resistant typhoid fever in Vietnam. Trans R Soc Trop Med Hyg 2004, 98:413–22.PubMedCrossRef 3. Gay K, Robicsek A, Strahilevitz J, Park CH, Jacoby G, Barrett TJ, Medalla F, Chiller TM, Hooper DC: Plasmid-mediated quinolone resistance in non-Typhi serotypes of Salmonella enterica. Clin Infect Dis 2006, 43:297–304.PubMedCrossRef 4. Xia S, Hendriksen RS, Xie Z, Huang L, Zhang J, Guo W, Alvocidib mouse Xu B, Ran L, Aarestrup FM: Molecular characterization and antimicrobial susceptibility of Salmonella from infections in humans in Henan province, China. J Clin Microbio 2009, 47:401–9.CrossRef 5. Clinical and Laboratory Standards Institute: Methods

for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. In Approved standard M7-A7. 7th edition. Clinical and Laboratory Standards Institute, Wayne, PA; 2006. 6. Clinical and Laboratory Standards Institute: Performance standards for antimicrobial susceptibility testing; 17 th informational supplement. CLSI INCB018424 mw M100-S17. Clinical and Laboratory Standards Institute, Wayne, PA; 2007. 7. Wain J, Hoa NTT, Chinh NT, Vinh H, Everett MJ, Diep TS, Day NPJ, Solomon T, White NJ, Piddock LJV, Parry CM: Quinolone-resistant Salmonella Typhi in Vietnam: Molecular basis of resistance and clinical response to treatment. Clin Infect Palmatine Dis 1997, 25:1404–10.PubMedCrossRef 8. Robicsek A, Strahilevitz J, Sahm DF, Jacoby GA, Hooper DC: qnr prevalence in ceftazidime-resistant Enterobacteriaceae isolates from the United States. Antimicrob Agents Chemother 2006, 50:2872–4.PubMedCrossRef 9. Park CH, Robicsek A, Jacoby GA, Sahm DF, Hooper DC: Prevalence in the United States of aac(6′)-Ib-cr encoding a ciprofloxacin-modifying

enzyme. Antimicrob Agents Chemother 2006, 50:3953–5.PubMedCrossRef 10. Giraud E, Brisabois A, Martel JL, Chaslus-Dancla E: Comparative studies of mutations in animal isolates and experimental in vitro and in vivo-selected mutants of Salmonella spp. suggest a counterselection of highly fluoroquinolone-resistant strains in the field. Antimicrob Agents Chemother 1999, 43:2131–7.PubMed 11. Pitout JD, Nordmann P, Laupland KB, Poirel L: Emergence of Enterobacteriaceae producing extend-spectrum β-lactamases (ESBL) in the community. J Antimicrob Agents Chemother 2005, 56:52–9.CrossRef 12. Munday CJ, Xiong J, Li C, Shen D, Hawkey PM: Dissemination of CTX-M type beta-lactamases in Enterobacteriaceae isolates in the People’s Republic of China. Inter J Antimicrob Agents 2004, 23:175–80.CrossRef 13. Siu LK, Lo JYC, Yuen KY, Chau PY, Ng MH, Ho PL: beta-lactamases in Shigella flexneri isolates from Hong Kong and Shanghai and a novel OXA-1-like beta-lactamase, OXA-30.

Comments are closed.